Page last updated: 2024-12-05

benzoxazolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzoxazolone: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-benzoxazolinone : A member of the class of benzoxazoles that is 2,3-dihydro-1,3-benzoxazole carrying an oxo group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6043
CHEMBL ID280323
CHEBI ID145233
SCHEMBL ID19555
MeSH IDM0067504

Synonyms (92)

Synonym
HMS1782P14
MLS000515797
smr000112271
BB 0243409
wln: t56 bmvoj
2-hydroxybenzoxazole
59-49-4
benzoxazole, 2-hydroxy-
benzoxazolone
usaf ek-5429
nsc-3812
benzoxazolinone
2-benzoxazolol
nsc3812
2-benzoxazolinone
2(3h)-benzoxazolone
carbamic acid, (2-hydroxyphenyl)-, gamma-lactone
ai3-19563
nsc 3812
ccris 6794
einecs 200-430-0
benzoxazolin-2-one
AG-996/01589042
2(3h)-benzoxazolinone
3h-1,3-benzoxazol-2-one
benzoxazoline,2-one
inchi=1/c7h5no2/c9-7-8-5-3-1-2-4-6(5)10-7/h1-4h,(h,8,9
1,3-benzoxazol-2(3h)-one
2-benzoxazolinone, 98%
benzoxazolin-2(3h)-one
benzoxalinone
STK397464
AC-10467
B0506
CHEMBL280323 ,
benzo[d]oxazol-2(3h)-one
3h-benzooxazol-2-one
bdbm50168000
CHEBI:145233
2,3-dihydro-2-oxo-1,3-benzoxazole
(3h)-1,3-benzoxazol-2-one
AKOS000120677
NCGC00246991-01
benzoxazol-2-one
unii-3x996q809v
3x996q809v ,
cas-59-49-4
tox21_202935
dtxcid8029280
NCGC00260481-01
dtxsid9049324 ,
HMS2269I20
AKOS016015266
1,3-benzoxazol-2-ol
FT-0608549
S5575
2-oxobenzoxazolidine
2-(3h)-benzoxazolone
benzoxazolidinone
1,3-benzoxazolin-2-one
2,3-dihydrobenzoxazol-2-one
3h-benzoxazol-2-one
2-benzoxazolone
BBL027537
SCHEMBL19555
AB00979475-01
9T-0220
2,3-dihydro-1,3-benzoxazol-2-one
1,3-benzoxazol-2(3h)-one #
carbamic acid, (2-hydroxyphenyl)-, .gamma.-lactone
Q-200241
STR04317
CS-W016534
69564-68-7
HY-W015818
mfcd00005716
Z56854468
2(3h)-benzoxazolone, 9ci
2-benzoxazolinone, 8ci
2-benzoxaxolol
2-hydroxy-benzoxazole
BBL101875
SY007021
STL555672
AMY2575
EN300-16991
CCG-266124
AC8520
Q27258173
benzoxazolinone, 2-
benzo[d]oxazol-2-ol
mfcd19300814

Research Excerpts

Overview

benzoxazolone nucleus is an ideal scaffold for drug design. It has discrete physicochemical profile, bioisosteric preference over pharmacokinetically weaker moieties, and weakly acidic behavior.

ExcerptReferenceRelevance
"The benzoxazolone nucleus is an ideal scaffold for drug design, owing to its discrete physicochemical profile, bioisosteric preference over pharmacokinetically weaker moieties, weakly acidic behavior, presence of both lipophilic and hydrophilic fragments on a single framework, and a wider choice of chemical modification on the benzene and oxazolone rings. "( Synthesis and biological profile of benzoxazolone derivatives.
Mall, T; Prasher, P; Sharma, M, 2023
)
1.74

Bioavailability

ExcerptReferenceRelevance
" When dosed as a nasal spray in rabbits, 3 was rapidly absorbed and showed good intranasal bioavailability (42%)."( The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2.
Civiello, RL; Conway, CM; Cook, DA; Davis, CD; Degnan, AP; Dubowchik, GM; Han, X; Jiang, XJ; Macci, R; Macor, JE; Mathias, NR; Moench, P; Pin, SS; Schartman, R; Signor, LJ; Thalody, G; Tora, G; Whiterock, V; Xu, C, 2013
)
0.39
" To increase the bioavailability and GluN2B affinity, the phenol of the potent benzazepine-based inhibitor, WMS-1410 (3), was replaced bioisosterically by a benzoxazolone moiety and the phenylbutyl side chain was conformationally restricted in a phenylcyclohexyl substituent."( Phenol-benzoxazolone bioisosteres of GluN2B-NMDA receptor antagonists: Unexpected rearrangement during reductive alkylation with phenylcyclohexanone.
Daniliuc, C; Frehland, B; Fröhlich, R; Goerges, G; Markus, A; Schepmann, D; Schreiber, JA; Seebohm, G; Wünsch, B, 2022
)
1.37

Dosage Studied

ExcerptRelevanceReference
" We developed a fast and reliable laboratory screening bioassay for grain crops that includes dose-response considerations as an integral part of the experimental design."( A novel laboratory screening bioassay for crop seedling allelopathy.
Belz, RG; Hurle, K, 2004
)
0.32
" ED50 doses of the pure compounds were estimated in dose-response experiments in Petri dishes, and these turned out to be much higher than the predicted maximum concentrations of DIMBOA, MBOA, and BOA in the soil water following incorporation."( Herbicidal effects of soil-incorporated wheat.
Kudsk, P; Mathiassen, SK; Mogensen, BB, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
allelochemicalA class of secondary metabolites developed by many plants to influence the behaviour, growth or survival of herbivores, and thus acting as a defence against herbivory.
phytoalexinA toxin made by a plant that acts against an organism attacking it.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzoxazoleCompounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.56230.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency31.62280.631035.7641100.0000AID504339
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.04870.001530.607315,848.9004AID1224841
gemininHomo sapiens (human)Potency0.29090.004611.374133.4983AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency100.00000.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)IC50 (µMol)11.90001.80001.80001.8000AID1324701
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)370.00000.00011.774010.0000AID241334
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (58)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
mitophagyUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of transcription from RNA polymerase II promoter by glucoseUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of glycolytic processUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of gluconeogenesisUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
chromatin organizationUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IIUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
protein O-linked glycosylationUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
apoptotic processUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
signal transductionUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
response to nutrientUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
protein processingUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
hemopoiesisUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
negative regulation of cell migrationUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
negative regulation of protein ubiquitinationUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
response to insulinUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
circadian regulation of gene expressionUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of Rac protein signal transductionUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of translationUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of proteolysisUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of insulin receptor signaling pathwayUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of lipid biosynthetic processUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of synapse assemblyUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of necroptotic processUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
cellular response to glucose stimulusUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of cold-induced thermogenesisUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
negative regulation of stem cell population maintenanceUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of stem cell population maintenanceUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
positive regulation of TORC1 signalingUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
protein bindingUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
acetylglucosaminyltransferase activityUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
chromatin DNA bindingUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
protein O-acetylglucosaminyltransferase activityUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nucleusUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
nucleoplasmUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
cytosolUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
plasma membraneUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
mitochondrial membraneUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
cell projectionUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
NSL complexUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
Sin3-type complexUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
glutamatergic synapseUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
histone acetyltransferase complexUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
protein N-acetylglucosaminyltransferase complexUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
protein-containing complexUDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunitHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1324708Inhibition of OGT in African green monkey COS7 cells assessed as reduction in global O-GlcNAcylation incubated for 4 hrs in glucose starvation medium followed by glucosamine and PUGNAc addition for 3 hrs by RL2 antibody based immunoblot method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1324698Binding affinity to OGT (unknown origin) assessed as modification at Cys590 residues following in-gel trypsin digestion by LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1324712Inhibition of OGT in African green monkey COS7 cells assessed as effect on cell surface glycan expression by measuring PNA level at 100 uM incubated for 7 hrs relative to DMSO control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1324715Inhibition of OGT in African green monkey COS7 cells assessed as effect on cell surface glycan expression by measuring reduction in PHA-E level at 100 uM incubated for 7 hrs relative to DMSO control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID212195The compound was tested for neurologic toxicity (rotarod) test for 30 min in mice; active at 300 mg/kg1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.
AID338668Antiinflammatory activity in Wistar rat peritoneal mast cells assessed as inhibition of concanavalin A-induced histamine release at 1000 uM treated 10 mins before concanavalin A challenge measured after 30 mins
AID133132Anticonvulsant activity in Maximal electroshock seizure test at 100 mg/kg i.p. in mice.1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.
AID140600Anticonvulsant activity in subcutaneous pentylenetetrazole seizure test for 30 min in mice; No activity/toxicity at 300 mg/kg.1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.
AID1389532Inhibition of DAAO (unknown origin) at 20 uM2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors.
AID1324710Effect on OGT levels in African green monkey COS7 cells at 100 uM incubated for 4 hrs in glucose starvation medium followed by glucosamine and PUGNAc addition for 3 hrs by RL2 antibody based immunoblot method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1324709Inhibition of OGT in African green monkey COS7 cells assessed as reduction in cellular OGA level at 100 uM incubated for 4 hrs in glucose starvation medium followed by glucosamine and PUGNAc addition for 3 hrs by RL2 antibody based immunoblot method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1324714Inhibition of OGT in African green monkey COS7 cells assessed as effect on cell surface glycan expression by measuring increase in GSL-I level at 100 uM incubated for 7 hrs relative to DMSO control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID241334Inhibitory concentration against recombinant human cytochrome P450 1A22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors.
AID212203The compound was tested for neurologic toxicity (rotarod) test for 4 hours in mice; no activity or no toxicity at 300 mg/kg1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.
AID1324701Inhibition of OGT (unknown origin) assessed as reduction in GlcNAc transfer to CKII peptide incubated for 60 mins by HPLC method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
AID133131The compound was tested for anticonvulsant activity in Maximal electroshock seizure test (MES) for 4 hr in mice(ip); no activity or toxicity at 300 mg/kg1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.
AID140603The anticonvulsant activity in subcutaneous pentylenetetrazole seizure test (sc Met) for 4 hr in mice; no activity or no toxicity at 300 mg/kg1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.
AID1324713Inhibition of OGT in African green monkey COS7 cells assessed as effect on cell surface glycan expression by measuring DBA level at 100 uM incubated for 7 hrs relative to DMSO control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1324711Inhibition of OGT in African green monkey COS7 cells assessed as effect on cell surface glycan expression by measuring ConA level at 100 uM incubated for 7 hrs relative to DMSO control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID1324699Binding affinity to OGT (unknown origin) assessed as modification at Cys531/Cys620 residues following in-gel trypsin digestion by LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
AID338669Antiinflammatory activity in Wistar rat peritoneal mast cells assessed as inhibition of IgE-induced histamine release at 1000 uM treated 10 mins before IgE challenge measured after 5 mins
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (133)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (11.28)18.7374
1990's4 (3.01)18.2507
2000's43 (32.33)29.6817
2010's53 (39.85)24.3611
2020's18 (13.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.31 (24.57)
Research Supply Index4.96 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other138 (97.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]